Humacyte, Inc. (HUMAW)

Market Cap	353.67M
Revenue (ttm)	517,000
Net Income (ttm)	-80.04M
Shares Out	155.12M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	420
Open	0.5001
Previous Close	0.5000
Day's Range	0.5001 - 0.5001
52-Week Range	0.1705 - 3.4700
Beta	2.00
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 21, 2025

About HUMAW

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 220
• Stock Exchange: NASDAQ
• Ticker Symbol: HUMAW
• Website: https://humacyte.com